REGENXBIO (RGNX) Competitors

Alector (NASDAQ:ALEC) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Is ALEC or RGNX more profitable?

REGENXBIO has a net margin of -270.74% compared to Alector's net margin of -290.66%. REGENXBIO's return on equity of -68.21% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-290.66%	-102.63%	-25.70%
REGENXBIO	-270.74%	-68.21%	-40.07%

Does the MarketBeat Community prefer ALEC or RGNX?

REGENXBIO received 279 more outperform votes than Alector when rated by MarketBeat users. Likewise, 65.65% of users gave REGENXBIO an outperform vote while only 61.38% of users gave Alector an outperform vote.

Company	Underperform	Outperform
Alector	Outperform Votes 151 61.38%	Underperform Votes 95 38.62%
REGENXBIO	Outperform Votes 430 65.65%	Underperform Votes 225 34.35%

Which has more risk and volatility, ALEC or RGNX?

Alector has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Do analysts rate ALEC or RGNX?

Alector currently has a consensus target price of $17.75, suggesting a potential upside of 286.71%. REGENXBIO has a consensus target price of $35.45, suggesting a potential upside of 276.38%. Given Alector's stronger consensus rating and higher possible upside, research analysts clearly believe Alector is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
REGENXBIO	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Which has better valuation and earnings, ALEC or RGNX?

Alector has higher revenue and earnings than REGENXBIO. Alector is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$97.06M	4.65	-$130.39M	-$1.80	-2.58
REGENXBIO	$90.24M	5.30	-$263.49M	-$5.27	-1.84

Do institutionals and insiders believe in ALEC or RGNX?

85.8% of Alector shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 9.1% of Alector shares are held by insiders. Comparatively, 13.1% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media favor ALEC or RGNX?

In the previous week, REGENXBIO had 1 more articles in the media than Alector. MarketBeat recorded 6 mentions for REGENXBIO and 5 mentions for Alector. REGENXBIO's average media sentiment score of 1.23 beat Alector's score of 0.18 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

REGENXBIO beats Alector on 12 of the 18 factors compared between the two stocks.